
Michael Betel (Fatty Liver Alliance, CAN)
(Speaker)
- Michael is the President and Founder of the Fatty Liver Alliance and has been a leader in the area of liver disease, in both commercial and not-for-profit organizations for over 30 years. He has held senior leadership roles including a Business Unit Director in Virology and Oncology at Hoffmann-La Roche, Director of Donor Relations at Canadian Blood Services, and as a sales and marketing leader at Schering-Plough. He was a Director on the board of a Canadian liver focused charity for 9 years (National Marketing and Communications Committee Member. Strategy Committee Member). He is now in his second year as the Chair for the Global Liver Institute's Liver Action Network, which includes 15 Patient Advocacy organizations. Michael is a member of community advisory boards for the Canadian Association for the Study of the Liver (CASL), Regeneron's NASH POWER Council, and PPD/Evidera Patient Voice in NASH Patient Advisory Board (PAB). Michael was an AASLD collaborator on the Fatty Liver Disease Research and Action Priorities consensus statement, an EASL participant in NASH consensus statement development, an AASLD participant at the Delphi expert panel developing consensus around the nomenclature of NAFLD. Michael has participated as a stakeholder at Mosaic (A multi-stakeholder multi-specialty NASH Trialists Think Tank), and is a member of the Liver Forum of Collaborative Research. He has presented and been on panels in Canada and internationally, including conferences such as EASL, the NIT Summit and the SLD Think Tank in 2024.